Renovaro Biosciences Inc. (RENB)

Renovaro Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Year Ending	Current	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Market Capitalization	199	33	102	238	196	175
Market Cap Growth	646.86%	-67.69%	-56.98%	21.35%	12.15%	-
Enterprise Value	207	37	100	224	195	162
PE Ratio	-	-0.83	-0.90	-8.89	-17.15	-9.69
PB Ratio	1.18	0.71	1.41	1.36	1.18	1.01
P/FCF Ratio	-35.02	-2.80	-6.49	-11.50	-18.39	-18.92
P/OCF Ratio	-35.19	-2.80	-6.50	-11.53	-18.72	-20.52
EV/EBITDA Ratio	-7.35	-0.94	-0.89	-8.51	-17.78	-9.04
EV/EBIT Ratio	-7.34	-0.94	-0.88	-8.47	-17.21	-9.01
EV/FCF Ratio	-35.78	-3.11	-6.36	-10.85	-18.29	-17.59
Debt / Equity Ratio	0.05	0.12	0.10	0.04	0.05	-
Debt / EBITDA Ratio	-0.16	-0.14	-0.06	-0.28	-0.69	-
Debt / FCF Ratio	-0.79	-0.47	-0.45	-0.35	-0.71	-
Quick Ratio	0.01	0.17	1.42	10.96	6.52	11.08
Current Ratio	0.06	0.23	1.48	11.08	6.70	11.25
Interest Coverage	-58.26	-67.38	-303.24	-69.73	-108.48	-418986.91
Return on Equity (ROE)	-70.60%	-63.50%	-80.10%	-16.10%	-6.70%	-11.60%
Return on Assets (ROA)	-55.90%	-52.80%	-71.80%	-15.00%	-6.40%	-10.30%
Return on Capital (ROIC)	-30.07%	-74.01%	-145.76%	-12.86%	-6.86%	-6.35%
Earnings Yield	-27.08%	-120.17%	-111.00%	-11.25%	-5.83%	-10.32%
FCF Yield	-5.46%	-35.75%	-15.40%	-8.70%	-5.44%	-5.28%
Buyback Yield / Dilution	-92.02%	-7.11%	-11.37%	-1.81%	-23.38%	-71.15%
Total Shareholder Return	-92.02%	-7.11%	-11.37%	-1.81%	-23.38%	-71.15%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).